摘要
AIM: To investigate the role of angiopoietin (Ang) -1, -2 and -4 and its receptors, Tie-1 and -2, in the growth and differentiation of gastrointestinal stromal tumors (GISTs).METHODS: Thirty GISTs, seventeen leiomyomas and six schwannomas were examined by immunohistochemistry in this study.RESULTS: Ang-1, -2 and -4 proteins were expressed in the cytoplasm of tumor cells, and Tie-1 and -2 were expressed both in the cytoplasm and on the membrane of all tumors. Immunohistochemical staining revealed that 66.7% of GISTs (20 of 30), 76.5% of leiomyomas (13 of 17) and 83.3% of schwannomas (5 of 6) were positive for Ang-1. 83.3% of GISTs (25 of 30), 82.4% of leiomyomas (14 of 17) and 100% of schwannomas (6 of 6) were positive for Ang-2. 36.7% of GISTs (11 of 30), 58.8% of leiomyomas (10 of 17) and 83.3% of schwannomas (5 of 6) were positive for Ang-4. 60.0% of GISTs (18 of 30), 82.4% of leiomyomas and 100% of schwannomas (6 of 6) were positive for Tie-1. 10.0% of GISTs (3 of 30), 94.1% of leiomyomas (16 of 17) and 33.3% of schwannomas (2 of 6) were positive for Tie-2. Tie-2 expression was statistically different between GISTs and leiomyomas (P < 0.001). However, there was no correlation between expression of angiopoietin pathway components and clinical risk categories.CONCLUSION: Our results suggest that the angiopoietin pathway plays an important role in the differentiation of GISTs, leiomyomas and schwannomas.
AIM： To investigate the role of angiopoietin （Ang） -1,-2 and -4 and its receptors, Tie-1 and -2, in the growth and differentiation of gastrointestinal stromal tumors （GISTs）. METHODS： Thirty GISTs, seventeen leiomyomas and six schwannomas were examined by immunohistochemistry in this study. RESULTS： Ang-1, -2 and -4 proteins were expressed in the cytoplasm of tumor cells, and Tie-1 and -2 were expressed both in the cytoplasm and on the membrane of all tumors. Immunohistochemical staining revealed that 66.7% of GISTs （20 of 30）, 76.5% of leiomyomas （13 of 17） and 83.3% of schwannomas （5 of 6） were positive for Ang-1. 83.3% of GISTs （25 of 30）, 82.4% of leiomyomas （14 of 17） and 100% of schwannomas （6 of 6） were positive for Ang-2. 36.7% of GISTs （11 of 30）, 58.8% of leiomyomas （10 of 17） and 83.3% of schwannomas （5 of 6） were positive for Ang-4. 60.0% of GISTs （18 of 30）, 82.4% of leiomyomas and 100% of schwannomas （6 of 6） were positive for Tie-1. 10.0% of GISTs （3 of 30）, 94.1% of leiomyomas （16 of 17） and 33.3% of schwannomas （2 of 6） were positive for Tie-2. Tie-2 expression was statistically different between GISTs and leiomyomas （P 〈 0.001）. However, there was no correlation between expression of angiopoietin pathway components and clinical risk categories. CONCLUSION： Our results suggest that the angiopoietin pathway plays an important role in the differentiation of GISTs, leiomyomas and schwannomas.
